Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06798701 · ClinicalTrials.gov registry record · NA

Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation

A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT06798701: Recruiting NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by Roswell Park Cancer Institute.

NCT06798701 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 28 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06798701, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This clinical trial compares the use of virtual reality to standard care for improving symptom management in patients undergoing hematopoietic stem cell transplantation (HSCT). Significant symptoms experienced by hospitalized HSCT patients include, but are not limited to, depression, tiredness, anxiety, drowsiness, lack of appetite, pain, and overall decreased quality of life and well-being. Virtual reality (VR) as an intervention can provide these patients with a much-needed escape from their reality and has proven results in clinical settings as a distraction therapy. VR technology targets the patient's auditory, visual, and physical contact/touch senses, and has been evidenced to improve depression, fatigue, anxiety, appetite, and pain. Virtual reality may improve symptom management in patients undergoing HSCT.

Primary Outcome

Firstly, the pattern of ESAS-r scores over time will be graphically examined. To account for the within-individual correlations, a generalized linear mixed model with appropriate link function will be applied. The time is measured by the number of days after treatment start and will be considered as a continuous variable. The effect of interest is the time by group interaction. Significant interaction implies different trajectories of ESAS-r composite scores over time. If the nonlinear patterns

Interventions

  • OTHER Survey Administration
  • OTHER Best Practice
  • OTHER Interview
  • PROCEDURE Virtual Reality

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2025-03-14
Est. Completion 2026-03-14
Phase NA
Roswell Park Cancer Institute

365 total trials

What NCT06798701 shows while recruiting

NCT06798701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.

NCT06798701 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06798701 about?

NCT06798701 is a clinical study titled "Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation". This clinical trial compares the use of virtual reality to standard care for improving symptom management in patients undergoing hematopoietic stem cell transplantation (HSCT). Significant symptoms experienced by hospitalized HSCT patients include, but are not limited to, depression, tiredness, anxi...

What is the current status of trial NCT06798701?

This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2025-03-14. Estimated completion is 2026-03-14.

What conditions does trial NCT06798701 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.

What interventions are being tested in trial NCT06798701?

The interventions under investigation include: Survey Administration (OTHER), Best Practice (OTHER), Interview (OTHER), Virtual Reality (PROCEDURE).

Who is sponsoring clinical trial NCT06798701?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06798701 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06798701's enrollment target sits among peer trials

28 152nd of 176 higher than 25 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06798701, the US trial registry maintained by the National Library of Medicine. NCT06798701 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.